Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-049546
Filing Date
2025-05-15
Accepted
2025-05-15 16:43:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5995
  Complete submission text file 0001104659-25-049546.txt   7947
Mailing Address 130 MAIN ST 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST 2ND FLOOR NEW CANAAN CT 06840 203-909-6430
Nantahala Capital Partners Limited Partnership (Filed by) CIK: 0001502725 (see all company filings)

EIN.: 201220305 | State of Incorp.: MA | Fiscal Year End: 1210
Type: SCHEDULE 13G/A

Mailing Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 382-3281
Senti Biosciences, Inc. (Subject) CIK: 0001854270 (see all company filings)

EIN.: 862437900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92581 | Film No.: 25954561
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)